Back to Search
Start Over
A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC.
- Source :
- Journal of Thoracic Oncology; 2007 Supplement 4, Vol. 2, pS413-S413, 1p
- Publication Year :
- 2007
Details
- Language :
- English
- ISSN :
- 15560864
- Volume :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 115803872
- Full Text :
- https://doi.org/10.1097/01.JTO.0000283298.56701.a0